29.12.2015 • NewsElaine BurridgeDrug DevelopmentRecipharm

Recipharm in Ophthalmic Collaboration with Alcon

Swedish drug developer and toll manufacturer Recipharm has signed a long-term agreement with Swiss eye-care treatment company Alcon, part of Novartis, to manufacture a range of ophthalmic products using its Blow Fill Seal technology. Recipharm said the agreement will add annual sales of more than €36 million.

As part of the deal, Recipharm will also acquire full ownership of Kaysersberg Pharmaceuticals for €18 million, with 75% of the sum to be paid this year and the remaining 25% in January 2016. The acquisition, which is being financed with existing funds, is expected to close on Dec. 31.

Kaysersberg’s main asset is a manufacturing facility in Kaysersberg, France, which currently supplies the ophthalmic products. The 260 people working at the site will transfer to Recipharm.

Thomas Eldered, Recipharm’s CEO, said Blow Fill Seal was a very interesting and growing technology. The process is an injection-molding technique for producing plastic unit doses of sterile drugs.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.